Decera Clinical Education Oncology Podcast

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.Presenter:  Donna Catamero, ANP-BC, OCN, CCRCAssociate Director, Myeloma Translational ResearchThe Mount Sinai Health SystemNew York, New YorkCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.Presenter:  Tiffany Richards, PhD, ANP-BC, AOCNPNurse PractitionerDepartment of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHouston, TexasCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include:Strategies for monitoring for disease progressionDisease, therapy, and patient considerations for treatment selection at first relapseNursing implications and supportive care considerations for patients receiving therapy for relapsed diseasePresenter:Charise Gleason, MSN, NP-BC, AOCNPAdvanced Practice Provider ChiefWinship Cancer InstituteAdjunct FacultyNell Hodgson Woodruff School of NursingEmory UniversityAtlanta, GeorgiaCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets:https://bit.ly/3ee9Ivs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include:IMWG criteria for diagnosing smoldering and active myelomaRisk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS stagingIndividualizing initial treatment for ASCT-ineligible myelomaSelecting optimal initial treatment for ASCT-eligible myelomaPresenter: Beth Faiman, PhD, MSN, APRN-BC, AOCNNurse PractitionerCleveland Clinic Taussig Cancer InstituteCleveland, OhioCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:  Adding bevacizumab to chemotherapy in frontline endometrial cancerLenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancerPARP inhibitor maintenance in ovarian cancerBevacizumab with or without PARP inhibitors in ovarian cancerPresenters:Linda R. Duska, MD, MPHLawrence W. Penniston MD Family Professor in Women’s Oncology ResearchDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyUniversity of Virginia School of MedicineCharlottesville, VirginiaRobert L. Coleman, MD, FACOG, FACSGynecologic Oncologist and Chief Scientific OfficerUS Oncology, US Oncology ResearchThe Woodlands, TexasLeslie Randall, MD, MAS  Diane Harris Wright Professor and DirectorDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyMassey Cancer CenterVirginia Commonwealth UniversityRichmond, VirginiaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3e6pZCM  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:  Whole exome sequencing for diagnosisWhen to treat asymptomatic tumorsGenetic testing of family membersChoosing a MEK inhibitorSupportive care for acneiform rashOther RAS pathway inhibitorsPresenters:Scott R. Plotkin, MD, PhDExecutive DirectorPappas Center for Neuro-OncologyProfessor of NeurologyHarvard Medical SchoolBoston, MassachusettsBrian D. Weiss, MDClinical Professor of PediatricsCancer and Blood Diseases Institute Division of Oncology  Medical DirectorSolid Tumor ProgramCincinnati Children’s Hospital Medical CenterCincinnati, OhioLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3AXckHQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,  Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including:  Germline and somatic mutation testingPARP inhibition in earlier stage diseasePARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapyPARP inhibition in taxane-sensitive patientsPresenters:Wassim Abida, MD, PhDAssistant MemberAssistant Attending PhysicianGenitourinary Oncology ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkJoaquin Mateo, MD, PhDGroup LeaderProstate Cancer Translational ResearchVall d'Hebron Institute of OncologyAttending PhysicianMedical OncologyVall d'Hebron University HospitalBarcelona, SpainCharles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3h1T5oR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:Current systemic therapy standards of care for patients with advanced HCCUse of single-agent immune checkpoint inhibitor therapy in the first-line settingAssessing bleeding riskUsing immunotherapy in patients with active HBV or HCV infectionsPresenters:David Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineUniversity of PennsylvaniaDirector of HepatologyCorporal Michael J. Crescenz VA Medical CenterPhiladelphia, PennsylvaniaThomas Karasic, MD  Assistant Professor of MedicineDepartment of Hematology-OncologyUniversity of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancerUpdated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancerResults from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancerHighly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancerA post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancersPresenters:David Scott Miller, MD, FACOG, FACSAmy and Vernon E. Faulconer Distinguished Chair in Medical ScienceDirector and Dallas Foundation Chair in Gynecologic OncologyProfessor of Obstetrics & GynecologyUniversity of Texas Southwestern Medical CenterMedical Director of Gynecologic OncologyChair, Cancer CommitteeParkland Health & Hospital SystemDallas, Texas  Melissa M. Hardesty, MD, MPHAffiliate Associate ProfessorOB/GYN/GYN OncologyUniversity of Alaska AnchorageGynecologic Oncologist and Managing PartnerAlaska Women’s Cancer CareAnchorage, AlaskaContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/3dAttwi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Suzanne Lentzsch, MD, PhD, and  Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:Selecting optimal triplet regimen after first relapseSequencing treatment options after multiple relapsesManaging patient expectations when selecting treatmentsEmerging treatment options for R/R MMPresenters:  Suzanne Lentzsch, MD, PhDDirector, Multiple Myeloma and Amyloidosis ProgramProfessor of MedicineDivision of Hematology/OncologyColumbia University Medical CenterNew York, New YorkSaad Z. Usmani, MD, MBA, FACPClinical Professor of MedicineDepartment of Hematologic Oncology & Blood DisordersDivision ChiefPlasma Cell Disorders DivisionLevine Cancer Institute/Atrium HealthCharlotte, North CarolinaSupported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.Link to full program, including an downloadable slidesets and an on-demand webcast:https://bit.ly/3gjr62p Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.